ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald also issued estimates for ORIC Pharmaceuticals’ FY2024 earnings at ($1.82) EPS. Several other research analysts have also commented on the company. Wedbush reaffirmed an outperform rating and set a […]
More Stories
Netflix’s Upcoming Drama, Husbands in Action, is Releasing Soon
Are you also a Korean drama lover? If yes, Good news! An all-new comedy drama is arriving soon on Netflix....
The Witness, TV Series: Release Date, Cast, Trailer, and Plot
Netflix’s upcoming documentary and television series are based on the real-life murder of Rachel Nickell in 1992. The Witness is...
15+ Famous White Actresses Over 40 Dominating the Film Industry
Want to know about popular white actresses over 40? Here, in this blog, I have mentioned some of the best...
Netflix Has Revealed The Release Date of The Thai Drama, The Evil Lawyer
Thailand’s upcoming courtroom drama, The Evil Lawyer, will be released soon. Netflix has announced the release date. The series features...
How to Build Your First Mobile App: A Step-by-Step Guide
Discover the essential steps in mobile app development, from defining your app idea to deploying and maintaining your application. This...
Essential Tips to Optimize Your Laptop for Maximum Performance
Enhance your laptop's performance with essential strategies covering hardware components, regular maintenance, and effective software management. Discover how upgrading your...